January 19, 2021
- The American Heart Association’s multi-year initiative, supported by Philips, aims to bring forward the latest education and clinical data to increase awareness for providers and patients in the pursuit of guideline-driven CIED care
- Every year in the
USA less than 30% of patients with CIED infections are treated properly in accordance with guidelines [1,2,3]
With the support of Philips, the American Heart Association’s national CIED infection initiative will work with medical professionals across a variety of specialities to prevent and properly treat infections resulting from cardiovascular implantable electronic devices such as pacemakers, implantable cardioverter-defibrillators and cardiac resynchronization devices.
Each year one million CIEDs are implanted worldwide [4] and one in 20 of these patients will develop a CIED infection [5] within three years. Support of efforts by the
Patients diagnosed with CIED infections are often treated with antibiotics, which is not an effective treatment option – 50-100% of patients treated with antibiotics alone will experience an infection relapse [6,7]. Clinical practice guidelines recommend extraction for all patients with a definite CIED infection, including complete device and lead removal. Too often, healthcare professionals lack awareness and experience in CIED infection management, increasing the chance of a missed infection diagnosis and prolonging inappropriate treatment. It is estimated that in the
“CIED infection is a major public health problem with substantial morbidity and mortality,” said
“By supporting the
“We are pleased to receive the support of Philips on this important effort to raise awareness for CIED infection care, reduce mortality rates among patients and improve guideline driven care of people living with CIED devices,” said
Learn more about CIED infection:
- Through
Philips ELITE Academy & Deviceinfection.com Philips has made resources available including education materials, data, case studies and Lead Management solutions to help educate providers in CIED infections. - Overcoming Barriers to Complete and Early Extraction for CIED Infection: A Narrative Review of the Epidemiological, Clinical and Economic Evidence. This presentation, recently presented at the AHA Scientific Sessions by
Ami Sood , M.D. from Philips, provides an overview of the many barriers patients face in receiving optimal treatments including challenges with infection diagnosis, patient referral to extraction centers and negative misconceptions regarding extraction procedures. American Heart Association at heart.org- If you are a patient seeking to learn more about managing your heart device and finding a lead extractor, visit the
Heart Rhythm Society for CIED management
[1] Sohail, M. R., Eby, E. L., Ryan, M. P., Gunnarsson, C., Wright, L. A., & Greenspon, A. J. (2016, Aug). Incidence, Treatment Intensity, and Incremental Annual Expenditures for Patients Experiencing a Cardiac Implantable Electronic Device Infection: Evidence From a Large US Payer Database 1-Year Post Implantation. Circ Arrhythm Electrophysiol, 9(8). https://doi.org/10.1161/circep.116.003929.
[2] Dai, M., Cai, C., Vaibhav, V., Sohail, M. R., Hayes, D. L., Hodge, D. O., Tian, Y., Asirvatham, R., Cochuyt, J. J., Huang, C., Friedman, P. A., & Cha, Y. M. (2019, Sep). Trends of Cardiovascular Implantable Electronic Device Infection in 3 Decades: A Population-Based Study. JACC Clin Electrophysiol, 5(9), 1071-1080. https://doi.org/10.1016/j.jacep.2019.06.016.
[3] Data on File. CIED Infection Treatment Inadequate Adherence to Guidelines.
[4] Greenspon A.J. J Am Coll Cardiol 58:1001–1006.; Kremers MS, Heart Rhythm 2013; 10:e59.
[5] Cantillon D. JACC EP. 2017.
[6] del Rio A, Anguera I, Miro JM, et al. Surgical treatment of pacemaker and defibrillator lead endocarditis: the impact of electrode lead extraction on outcome. Chest 2003;124:1451–9.
[7] Chua, J.D., et al. (2000). Diagnosis and management of infections involving implantable electrophysiologic cardiac devices. Annals of Internal Medicine, 133(8): 604-608.
[8] Le, K. Y., et al. (2011, Nov). Impact of timing of device removal on mortality in patients with cardiovascular
implantable electronic device infections. Heart Rhythm, 8(11), 1678-1685. 21.
[9] Greenspon, A. J., et al. (2018, May). Treatment patterns, costs, and mortality among Medicare beneficiaries
with CIED infection. Pacing Clin Electrophysiol, 41(5), 495-503.
For further information, please contact:
Joost Maltha
Philips Global Press Office
Tel: +31 6 10 55 8116
E-mail: joost.maltha@philips.com
Philips Image Guided Therapy
Tel: + 31 622 698 001
E-mail: fabienne.van.der.feer@philips.com
About Royal Philips
Royal Philips (NYSE: PHG, AEX: PHIA) is a leading health technology company focused on improving people's health and well-being, and enabling better outcomes across the health continuum – from healthy living and prevention, to diagnosis, treatment and home care. Philips leverages advanced technology and deep clinical and consumer insights to deliver integrated solutions. Headquartered in
Attachment
- Physician talks to patient
Source: Royal Philips
2022 GlobeNewswire, Inc., source